Reuters logo
3 个月前
BRIEF-Novan reports positive topline results with SB208 in phase 2 trial
2017年4月12日 / 上午10点15分 / 3 个月前

BRIEF-Novan reports positive topline results with SB208 in phase 2 trial

1 分钟阅读

April 12 (Reuters) - Novan Inc

* Novan reports positive topline results with SB208 in phase 2 trial

* Novan Inc - SB208 gel, at both 4% and 16% concentrations, demonstrated a statistically significant effect (p<0.05) versus vehicle in a clinical trial

* "Results from this phase 2 trial with SB208 confirm fungicidal activity of nitric oxide observed in our preclinical studies"

* Novan - Based on data from SB208 phase 2 dose-ranging trial, co will evaluate late stage development opportunities in superficial cutaneous fungal infections

* Novan - Will evaluate opportunities such as a phase 2 trial in patients with onychomycosis, to be initiated as early as second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below